As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Individuals with vs. without interstitial lung disease faced an elevated risk for lung cancer and histological subtypes of ...

Some of the most interesting data are precisely those illustrating the reality of clinical practice of physicians attending ...

Roche’s hopes of getting astegolimab to regulators this year took a hit after the anti-ST2 antibody failed to reduce flare-ups in a phase 3 study.

Patients with COPD and chronic hypercapnic respiratory failure on noninvasive ventilation report similar quality of life across age groups.

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.

AstraZeneca has announced a new clinical study titled ‘Exacerbations and Their Outcomes in Egyptian Patients (EXACOS EG Population),’ which aims to explore the burden of severe exacerbations ...

Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.

Learn about a new drug for chronic obstructive pulmonary disease (COPD). A top expert explains mepolizumab and its benefits, how it works, and its impact on COPD treatment.

US News: A declassified report reveals alarming details about Hillary Clinton's health during the 2016 election, accessed by Russian intelligence, raising questions about the implications for her ...